Efficacy and safety for the therapy of liver cancer by combination Sorafenib with other therapies: a literature review

Abstract

Background and Objective: Liver cancer is one of the top ten cancers in the world with new cases occurring in per year. At present, the etiology and exact molecular mechanism of liver cancer are not fully understood. Today, Sorafenib, as a multi-target drug for the treatment of liver cancer in the world, has made obvious progress in many aspects after decades of clinical trials. Many therapeutic regimens have been created and reached a better prognosis which centered on Sorafenib. In order to get a general understanding of sorafenib in therapy for liver cancer, we review the current status of sorafenib solely or in combination with other therapies for liver cancer treatment. Methods: The references in this review are from PubMed, web of science and CBM (China biomedical literature service system) with the key words of Sorafenib, HCC and so on. Most of them are published within ten years and their types include clinical trials, meta-analysis, randomized controlled trials and research articles as well. Key Content and Findings: This article mainly discusses the current situation of clinical application of sorafenib as a targeted drug and the combined therapeutic effect of sorafenib and other therapies, which provides a new way for researchers to improve the clinical efficacy of targeted therapy for liver cancer. Conclusions: Sorafenib, as the first line drug for patients with liver cancer, has significantly improved the patients’ survival by joint or separate way. In the future, more treatment methods may be developed and bring more benefit for liver cancer patients. Of course, some attention should be paid to side effects in patients, including skin redness, hair loss, diarrhea. Lenvatinib, liver neoplasms, and